This Company Could Be the Next CETX or CANF

LAS VEGAS, NV / ACCESSWIRE / October 5, 2015 / What do Cemtrex, Inc. (CETX) and Can-Fite BioPharma Ltd. (CANF) have in common? They both made investors boatloads of money over the past month, with 100 and 200% moves respectively. That and they both remind us of Propanc Health Group Corporation (PPCH).

PPCH is a cancer (oncology) focused biotech developing potential pharmaceuticals for the treatment of colorectal and pancreatic cancer. PPCH has had an amazing 2015 for investors making runs as large as 13,000%. Since reaching a high of $0.134 the stock has come down to its current low of $0.029.

Their lead patent has recently been accepted in Australia, after receiving approval in South Africa and New Zealand. With the United States and European Union still examining the approval, these major dominoes falling could be enormous for PPCH investors. In the meantime, you can imagine savvy investors have begun accumulating at these low prices.

Cemtrex, Inc. (CETX) was a similar OTC darling that fell out of favor briefly. Since hitting its lows the stock made a 100% run and is now trading on the Nasdaq. Investors who weathered the brief storm are now sitting pretty. This story arc is very similar to what we see happening with PPCH. CETX's Market Cap was around $15million when the recent move began. PPCH's is currently around $10 million.

As a biotech, Propanc, has the benefit of being in one of this year's hottest sectors. One of the sectors recent leaders is Can-Fite BioPharma Ltd. (CANF). CANF made a 211% move in the past few weeks. CANF has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its drug CF102, for use as a second line treatment for hepatocellular carcinoma, which is the most common form of lung cancer. Fast Track Designation is granted to new medical drugs that answer unmet medical requirements of patients and the approval is likely to speed up the development of CF102, which was already given an Orphan Drug designation by the institution.

CANF’s treatment is currently in phase 2 testing and the company is likely to complete the patient enrollment process in the first half of 2016. It already received the European Medicines Agency's approval for dosing patients in its global phase 2 study of CF102 in May of this year. If the company succeeds in its upcoming study and approval phase, it could open a $2 billion market for the company, which is primarily dominated by Nexavar, a drug co-developed and marketed by Bayer AG (ADR)(OTCMKTS:BAYRY) and Onyx Pharmaceuticals (NASDAQ:ONXX). Nexavar reported annual sales of $874 million in 2014. Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) filed its semi-annual report on August 27 for the six months ended on June 30, posting a net loss of $2.19 million and cash assets worth $7.75 million.

Another biotech leader that PPCH could follow in the footsteps of is Anthera Pharmaceuticals Inc. (ANTH). The company made a 150% move for investors over the course of the summer. Many research firms still believe the company has room to move including Zacks Research which said in a recent release: "Investors shouldn't be surprised to note that we have ANTH as a security with a Zacks Rank #2 (Buy) and a Momentum Score of 'B'."

Propanc has been a big winner for investors this year, and looks ready to continue its winning ways heading into 2016. The above companies all show similar paths Propanc could be on its way to taking.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns, Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For this press release ACR Communication, LLC. has been compensated $6,000 by Regal Consulting, LLC. on behalf of Propanc Health Group, Corp.

Contact:

Acrlasvegas@gmail.com

SOURCE: ACR Communications LLC

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.